Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 1 hour ago
Charles River debuts AI diagnostic tool to cut down pathology timelines
about 1 hour ago
Charles River is rolling out an artificial intelligence-backed digital pathology platform with...
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
about 2 hours ago
If any proof was needed that big money is still available for...
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
about 4 hours ago
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure...
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
about 5 hours ago
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in...
Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test
about 7 hours ago
Roche has secured a European CE mark for its second Alzheimer’s test...
Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
about 7 hours ago
Bayer has removed a protein therapeutic for hypertension and a treatment for...
Blood-based approach could detect early heart, kidney disease, study finds
about 9 hours ago
Scientists know that damage to microscopic blood vessels can provide an early...
Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
about 10 hours ago
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has...
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed
about 12 hours ago
Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying...
Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
1 day ago
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top...
Amid M&A rumor, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
1 day ago
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in...
Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech
1 day ago
Novo Nordisk has found the latest buyer for one of its orphaned...